<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597179</url>
  </required_header>
  <id_info>
    <org_study_id>2012-08-065</org_study_id>
    <nct_id>NCT02597179</nct_id>
  </id_info>
  <brief_title>Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer</brief_title>
  <official_title>Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate and analyse genomic profiles in patient with
      breast cancer who failed standard treatment, refractory and young breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis is that genomic profiling measured by CancerSCAN, cfDNA, Whole exome
      sequencing (WES), Whole transcriptome sequencing (WTS), FACS(Fluorescence-Activated Cell
      Sorting), cytokine and immunologic signature analysis would be helpful to find out tolerance
      for chemotherapy and innovate new therapeutic strategies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Mutated Genes and/or Abnormal Gene expression and/or Different Immune signature That Affect to Treatment Outcome.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Metastatic Breast Cancer, Young Breast Cancer</arm_group_label>
    <description>Patients with feasible biopsy site.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, tumor samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Histologically or cytologically conrfirmed breast cancer that is either metastatic or young
        breast cancer(≤ 40 years of age) with feasible biopsy site.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed breast cancer that is either metastatic or
             young breast cancer(≤ 40 years of age).

          2. HER2 positive patient who failed HER2 target therapy including trastuzumab with
             feasible biopsy site.

          3. Triple Negative Breast Cancer patient who failed standard therapy with feasible biopsy
             site.

          4. Hormone Receptor positive patient who failed standard therapy with feasible biopsy
             site.

          5. Age ≥ 21 years

          6. Written informed consent

        Exclusion Criteria:

          1. No feasible biopsy site

          2. No written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Young-hyuck Im, MD, Ph.D</last_name>
    <phone>82-2-3410-3445</phone>
    <email>imyh00@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-Gu</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Hyuck Im, MD, Ph.D</last_name>
      <phone>82-2-3410-3445</phone>
      <email>imyh00@skku.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Young-Hyuck Im</investigator_full_name>
    <investigator_title>MD, Ph.D, Division of Hematology-Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

